D. Cherepanov

发表

US Norms for Six Generic Health-Related Quality-of-Life Indexes From the National Health Measurement Study

M. Palta, D. Fryback, D. Feeny, 2007, Medical care.

IDENTIFICATION OF POTENTIAL MARKERS FOR CUSHING DISEASE.

M. Broder, M. Neary, D. Cherepanov, 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Comparison of 5 Health-Related Quality-of-Life Indexes Using Item Response Theory Analysis

M. Palta, D. Bolt, D. Fryback, 2010, Medical decision making : an international journal of the Society for Medical Decision Making.

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

D. Cherepanov, S. Kambhampati, R. Rifkin, 2020, Clinical Lymphoma Myeloma and Leukemia.

Standard Error of Measurement of 5 Health Utility Indexes across the Range of Health for Use in Estimating Reliability and Responsiveness

M. Palta, D. Fryback, D. Feeny, 2011, Medical decision making : an international journal of the Society for Medical Decision Making.

Burden of illness, annual healthcare utilization, and costs associated with commercially insured patients with Cushing disease in the United States.

M. Broder, M. Neary, D. Cherepanov, 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases

M. Broder, M. Neary, D. Cherepanov, 2014, Pituitary.

Annual health care costs and utilization in adults taking long or short acting antiepileptic monotherapy

J. Cramer, M. Broder, D. Cherepanov, 2013 .

Underlying Dimensions of the Five Health-Related Quality-of-Life Measures Used in Utility Assessment: Evidence From the National Health Measurement Study

M. Palta, D. Fryback, D. Cherepanov, 2010, Medical care.

Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process

M. Choti, J. Sicklick, M. Broder, 2020, Cancers.

Follow-up intervals in patients with Cushing’s disease: recommendations from a panel of experienced pituitary clinicians

M. Broder, M. Neary, D. Cherepanov, 2017, Pituitary.

Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.

M. Broder, P. Philip, A. Benson, 2015, World journal of gastroenterology.

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

G. Morgan, A. Palumbo, N. Puig, 2021, Annals of Hematology.

Burden of skeletal-related events in prostate cancer: unmet need in pain improvement

M. Broder, D. Cherepanov, Y. Linhares, 2014, Supportive Care in Cancer.

Clinical utility of the 12-gene DCIS score assay: Impact on treatment (Tx) recommendations.

M. Broder, D. Cherepanov, A. Sing, 2014 .

Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.

M. Broder, M. Neary, D. Cherepanov, 2016, World journal of gastroenterology.

Treatment patterns in Cushing’s disease patients in two large United States nationwide databases: application of a novel, graphical methodology

M. Broder, M. Neary, D. Cherepanov, 2015, Pituitary.

The association between biochemical control and cardiovascular risk factors in acromegaly

M. Broder, M. Neary, A. Mamelak, 2017, BMC Endocrine Disorders.

Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma

P. Hari, D. Cherepanov, K. McCarrier, 2021, Supportive Care in Cancer.

Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant

D. Cherepanov, A. Chari, E. Farrelly, 2022, Cancer medicine.

Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review

D. Cherepanov, N. Yurgin, T. Bentley, 2018, Current medical research and opinion.

Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center

M. Broder, M. Neary, A. Mamelak, 2017, BMC Endocrine Disorders.

Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors: Consensus Results From a Modified Delphi Process

M. Broder, A. Benson, D. Cherepanov, 2013, Pancreas.

BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.

M. Broder, M. Neary, D. Cherepanov, 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Incidence of Cushing’s syndrome and Cushing’s disease in commercially-insured patients <65 years old in the United States

M. Broder, M. Neary, D. Cherepanov, 2015, Pituitary.

The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.

M. Broder, D. Cherepanov, A. Powers, 2014, American health & drug benefits.

Gender differences in health-related quality-of-life are partly explained by sociodemographic and socioeconomic variation between adult men and women in the US: evidence from four US nationally representative data sets

M. Palta, D. Fryback, D. Cherepanov, 2010, Quality of Life Research.

INCIDENCE AND PREVALENCE OF ACROMEGALY IN THE UNITED STATES: A CLAIMS-BASED ANALYSIS.

M. Broder, M. Neary, D. Cherepanov, 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care.

M. Broder, D. Cherepanov, A. Powers, 2012, American health & drug benefits.

Healthcare utilization and costs in adults with stable and uncontrolled epilepsy

J. Cramer, M. Broder, D. Cherepanov, 2014, Epilepsy & Behavior.

Socioeconomic status and age variations in health-related quality of life: results from the national health measurement study.

M. Palta, D. Fryback, D. Feeny, 2009, The journals of gerontology. Series B, Psychological sciences and social sciences.

Gender Differences in Multiple Underlying Dimensions of Health-related Quality of Life Are Associated with Sociodemographic and Socioeconomic Status

M. Palta, D. Fryback, R. Hays, 2011, Medical care.

Protecting the gains: What changes are needed to prevent a reversal of the downward cardiovascular disease mortality trend?

M. Broder, D. Cherepanov, A. Diamant, 2018, Clinical cardiology.

A single question about a respondent’s perceived financial ability to pay monthly bills explains more variance in health utility scores than absolute income and assets questions

J. Hanmer, D. Cherepanov, 2016, Quality of Life Research.

Outcomes research examining treatments, quality of life and costs in HER2-negative and triple-negative metastatic breast cancer: a systematic literature review.

M. Broder, D. Cherepanov, C. Pelletier, 2018, Journal of comparative effectiveness research.

Race and gender associations between obesity and nine health-related quality-of-life measures

M. Palta, D. Fryback, D. Feeny, 2011, Quality of Life Research.

Consensus treatment guidelines for urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.

M. Choti, J. Sicklick, M. Broder, 2017 .

M. Palta, D. Fryback, R. Hays, 2011, Quality of Life Research.

Healthcare utilization and costs in children with stable and uncontrolled epilepsy

J. Cramer, M. Broder, D. Cherepanov, 2014, Epilepsy & Behavior.

Health Condition Impacts in a Nationally Representative Cross-Sectional Survey Vary Substantially by Preference-Based Health Index

M. Palta, D. Fryback, D. Feeny, 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.

M. Broder, M. Neary, D. Cherepanov, 2015, World journal of gastroenterology.

Global epidemiology of amyloid light-chain amyloidosis

D. Faller, D. Cherepanov, D. Romanus, 2022, Orphanet Journal of Rare Diseases.

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.

M. Dimopoulos, D. Cherepanov, R. Benjamin, 2023, Clinical lymphoma, myeloma & leukemia.

The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12‐gene DCIS score™ result

M. Broder, D. Cherepanov, E. Chang, 2015, Journal of surgical oncology.

Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib

D. Cherepanov, S. Kambhampati, R. Rifkin, 2020, Clinical Lymphoma Myeloma and Leukemia.

Validation of an ICD-9-based claims algorithm for identifying patients with chronic idiopathic/spontaneous urticaria.

M. Broder, D. Cherepanov, E. Chang, 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

A Retrospective Study of the Impact of 21-Gene Recurrence Score Assay on Treatment Choice in Node Positive Micrometastatic Breast Cancer

M. Broder, D. Cherepanov, K. Fox, 2015, Pharmaceuticals.

Real‐world treatment patterns and outcomes in non‐transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom

S. Corman, H. Vikis, D. Cherepanov, 2020, European journal of haematology.

Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study

N. Puig, M. Boccadoro, D. Cherepanov, 2019, Blood.

Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

D. Cherepanov, M. Duh, R. Bhak, 2023, Hematology.

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.

M. Broder, M. Neary, D. Cherepanov, 2015, World journal of gastroenterology.

Estimating the Global Epidemiology of Amyloid Light-Chain Amyloidosis With an Incidence-to-Prevalence Model

D. Faller, D. Cherepanov, D. Romanus, 2019, Clinical Lymphoma Myeloma and Leukemia.